From Paper to Patients: Revealing the Impact of the United Kingdom’s Health Technology Assessment Policies on Advanced Therapy Medicinal Products
View the poster here
ATMPs offer ground-breaking opportunities for the treatment of disease, but value demonstration is often inhibited by data generation challenges in small populations, reliance on single-arm studies, and insufficient follow-up to show a curative effect.
Using the Lightning Insights stakeholder network, primary research was conducted with three former HTA members and three industry stakeholders from the UK to explore the impact of four UK policies (the ILAP, HST programme, IMF and disease severity modifier) on evaluation of ATMPs in the UK.
To learn more about this recent research and how Lightning Insights was used to inform this poster, contact our expert team.
Article published 14 November 2023.